Adverse Reactions to Biologic Therapy

Immunology and Allergy Clinics of North America

Volumn 37, Issue 2, 2017, Pages 397-412

  Patel, Sheenal V ^a   Khan, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biologic agents; Delayed reaction; Drug desensitization; Infusion reaction; Monoclonal antibodies; Omalizumab; Rituximab

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; BENRALIZUMAB; BETA INTERFERON; BIOLOGICAL PRODUCT; ETANERCEPT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 2; MEPOLIZUMAB; OMALIZUMAB; PLACEBO; RESLIZUMAB; RITUXIMAB;

ADVERSE OUTCOME; ANAPHYLAXIS; ASTHMA; BACKACHE; BIOLOGICAL THERAPY; CLINICAL EVALUATION; CROSS REACTION; CYTOKINE RELEASE; DESENSITIZATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERSENSITIVITY; INFUSION RELATED REACTION; INJECTION SITE REACTION; MOLECULAR WEIGHT; NAUSEA; NONHUMAN; OROPHARYNX PAIN; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN TEST; ADVERSE DRUG REACTION; DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES;

BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; DESENSITIZATION, IMMUNOLOGIC; DISEASE MANAGEMENT; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 85014098419     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2017.01.012     Document Type: Review

References (42)

1. 1 Adkinson, N.F., Bochner, B.S., et al. (eds.) Middleton's allergy principles in practice: Chapter 5: cytokines in allergic inflammation, 2014, Elsevier Sanders, Philadelphia.
2. 2 Pichler, W.J., Adverse side-effects to biological agents. Allergy 61:8 (2006), 912–920.
3. 3 Aubin, F., Carbonnel, F., Wendling, D., et al. The complexity of adverse side-effects to biological agents. J Crohns Colitis 7:4 (2013), 257–262.
4. 4 Naisbitt, D.J., Gordon, S.F., Pirmohamed, M., et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 23 (2000), 483–507.
5. 5 Hausmann, O.V., Seitz, M., Villiger, P.M., et al. The complex clinical picture of side effects to biologicals. Med Clin North Am 94:4 (2010), 791–804.
6. 6 Vasquez, E.M., Fabrega, A.J., Pollak, R., OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 27 (1995), 873–874.
7. 7 Suntharalingam, G., Perry, M.R., Ward, S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006), 1018–1028.
8. 8 Bugelski, P.J., Achuthanadam, R., Capocasale, R.J., et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5:5 (2009), 499–521.
9. 9 Abramowicz, D., Crusiaux, A., Goldman, M., Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med, 327, 1992, 736.
10. 10 Chung, C.H., Mirakhur, B., Chan, E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:11 (2008), 1109–1117.
11. 11 Lenz, H.J., Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:5 (2007), 601–609.
12. 12 Makatsori, M., Kiani-Alikhan, S., Manson, A.L., et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 107 (2014), 821–828.
13. 13 Devos, S.A., Van Den Bossche, N., De Vos, M., et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206 (2003), 388–390.
14. 14 Chan, J.L., Davis-Reed, L., Kimball, A.B., Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 3 (2004), 315–318.
15. 15 Perez-Soler, R., Saltz, L., Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23:22 (2005), 5235–5246.
16. 16 Cheifetz, A., Mayer, L., Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72 (2005), 250–256.
17. 17 Cheifetz, A., Smedley, M., Martin, S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003), 1315–1324.
18. 18 Xolair (omalizumab) [Product insert], 2007, Genentech, Inc, South San Francisco.
19. 19 Galvao, V.R., Castells, M.C., Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract 3 (2015), 175–185.
20. 20 Brennan, P.J., Rodriguez Bouza, T., Hsu, F.I., et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124 (2009), 1259–1266.
21. 21 Cox, L., Platts-Mills, T.A., Finegold, I., et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120 (2007), 1373–1377.
22. 22 Cox, L., Lieberman, P., Wallace, D., et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 128 (2011), 210–212.
23. 23 Price, K.S., Hamilton, R.G., Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28 (2007), 313–319.
24. 24 Lieberman, P., The unusual suspects: a surprise regarding reactions to omalizumab. Allergy Asthma Proc 28 (2007), 259–261.
25. 25 Lieberman, P., Rahmaoui, A., Wong, D.A., et al. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 105 (2010), 493–495.
26. 26 Dreyfus, D.H., Randolph, C.C., Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 96 (2006), 624–627.
27. 27 Owens, G., Petrov, A., Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 6 (2011), 339–342.
28. 28 Khan DA. Adverse Reactions to Biological Agents: Opportunities for the Allergist American College of Allergy, Asthma, and Immunology National Meeting. San Antonio (TX), November 7, 2015.
29. 29 Bel, E.H., Wenzel, S.E., Thompson, P.J., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:13 (2014), 1189–1197.
30. 30 Nucala (mepolizumab) [Product insert], 2015, GlaxoSmithKline LLC, Research Triangle Park (NC).
31. 31 Cinqair (reslizumab) [Product insert], 2016, Teva Respiratory, LLC, Frazer (PA).
32. 32 Castro, M., Zangrilli, J., Wechsler, M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 3 (2015), 355–366.
33. 33 Laviolette, M., Gossage, D.L., Gauvreau, G., et al. Effect of benralizumab on airway eosinophils in asthma with sputum eosinophilia. J Allergy Clin Immunol 132:5 (2013), 1086–1096.e5.
34. 34 Tan, L.D., Bratt, J.M., Godor, D., et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy 9 (2016), 71–81.
35. 35 Gorman, C., Leandro, M., Isenberg, D., B cell depletion in autoimmune disease. Arthritis Res Ther 5:Suppl 4 (2003), S17–S21.
36. 36 Van Vollenjoven, R.F., Emery, P., Bingham, C.O. 3rd, et al. Extended report: long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72 (2013), 1496–1502.
37. 37 Rituxan (rituximab) [Package insert], 1997, Genentech Inc, South San Francisco.
38. 38 Karmachayra, P., Poudel, D.R., Pathak, R., et al. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum 45:3 (2015), 334–340.
39. 39 Zeltser, R., Valle, L., Tanck, C., et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha-receptor: Fc fusion protein. Arch Dermatol 137 (2001), 893–899.
40. 40 Quercia, Q., Emiliani, F., Foschi, F.G., et al. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol, 106, 2011, 547.
41. 41 Bavbek, S., Ataman, S., Akinci, A., et al. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients. J Allergy Clin Immunol Pract 3:4 (2015), 639–640.
42. 42 Sloane, D., Govindarajulu, U., Harrow-Mortelliti, J., et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 4 (2016), 497–504.